Aptevo Therapeutics Inc.: 10-Q filed 2025-08-11
What Aptevo Therapeutics Inc. reported in its quarterly report filed 2025-08-11 (fiscal Q2 2025): 25 published measures, 75 facts as tagged in accession 0000950170-25-106247.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-08-11
- Fiscal period
- fiscal Q2 2025
- Accession
- 0000950170-25-106247 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Aptevo Therapeutics Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 15,624,000 | USD | |
| At 2024-12-31 | 15,591,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 9,100,000 | USD | |
| At 2024-12-31 | 10,836,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 6,524,000 | USD | |
| At 2025-03-31 | -1,473,000 | USD | |
| At 2024-12-31 | 4,755,000 | USD | |
| At 2024-06-30 | 4,463,000 | USD | |
| At 2024-03-31 | 6,103,000 | USD | |
| At 2023-12-31 | 12,221,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 9,410,000 | USD | |
| At 2024-12-31 | 8,714,000 | USD | |
| At 2024-06-30 | 8,066,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -6,204,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -12,612,000 | USD | 181 |
| 2025-01-01 to 2025-03-31 | -6,408,000 | USD | 90 |
| 2024-04-01 to 2024-06-30 | -5,883,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -12,717,000 | USD | 182 |
| 2024-01-01 to 2024-03-31 | -6,834,000 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | -13,668,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | -12,804,000 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 14,364,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 3,966,000 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | -260,189,000 | USD | |
| At 2024-12-31 | -247,577,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 738,149 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 408,985 | shares | 181 |
| 2024-04-01 to 2024-06-30 | 4,756 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 2,852 | shares | 182 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 738,149 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 408,985 | shares | 181 |
| 2024-04-01 to 2024-06-30 | 4,756 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 2,852 | shares | 182 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -8.4 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -30.84 | USD/shares | 181 |
| 2024-04-01 to 2024-06-30 | -1,236.96 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -4,458.98 | USD/shares | 182 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -8.4 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -30.84 | USD/shares | 181 |
| 2024-04-01 to 2024-06-30 | -1,236.96 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -4,458.98 | USD/shares | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 432,000 | USD | |
| At 2024-12-31 | 543,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 17,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 992,000 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -6,226,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -12,706,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -6,024,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -13,007,000 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 11,081,000 | USD | |
| At 2024-12-31 | 10,659,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 4,891,000 | USD | |
| At 2024-12-31 | 6,207,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 3,328,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 6,961,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 3,643,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 7,395,000 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 3,224,156 | shares | |
| At 2024-12-31 | 72,922 | shares |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 4,111,000 | USD | |
| At 2024-12-31 | 4,389,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | -12,612,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | -12,717,000 | USD | 182 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 2,898,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 5,745,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 2,381,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 5,612,000 | USD | 182 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 110,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 197,000 | USD | 182 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 22,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 94,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 141,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 290,000 | USD | 182 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 688,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 688,000 | USD | 182 |
Inspect the source
- Entity
- Aptevo Therapeutics Inc. / CIK 0001671584
- Captured
- 2026-09-21T17:24:21.399Z
- SEC response SHA-256
79c4e035e65510fb4364121cfd545dab16c6a89232545f5c4f8a36a1cb035444
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001671584.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))